EcoDrugPlus

Atrial Natriuretic Peptide Receptor 1-Like

Ensembl ID : ENSSTUG00000013503
Gene Symbol: LOC115179822
2 Cross references
185 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 2-Like

Ensembl ID : ENSSTUG00000010074
Gene Symbol: LOC115159593
2 Cross references
178 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 2-Like

Ensembl ID : ENSSTUG00000036872
Gene Symbol: LOC115204045
2 Cross references
178 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSSTUG00000009840
Gene Symbol: LOC115165064
3 Cross references
205 Possible Orthologues:

Atrial Natriuretic Peptide Receptor 3-Like

Ensembl ID : ENSSTUG00000003112
Gene Symbol: LOC115200656
3 Cross references
206 Possible Orthologues:

Aurora Kinase B-Like

Ensembl ID : ENSSTUG00000027210
Gene Symbol: LOC115152346
3 Cross references
200 Possible Orthologues:

Aurora Kinase B-Like

Ensembl ID : ENSSTUG00000049917
Gene Symbol: LOC115197586
3 Cross references
199 Possible Orthologues:

Aurora Kinase C-Like

Ensembl ID : ENSSTUG00000009070
Gene Symbol: LOC115207352
3 Cross references
233 Possible Orthologues:

Bcl-2-Like Protein 1

Ensembl ID : ENSSTUG00000034465
Gene Symbol: LOC115168617
3 Cross references
220 Possible Orthologues:

Bcl-2-Like Protein 1

Ensembl ID : ENSSTUG00000034849
Gene Symbol: LOC115165991
3 Cross references
221 Possible Orthologues:

Beta-1 Adrenergic Receptor-Like

Ensembl ID : ENSSTUG00000035292
Gene Symbol: LOC115200119
3 Cross references
191 Possible Orthologues:

Beta-2 Adrenergic Receptor

Ensembl ID : ENSSTUG00000011494
Gene Symbol: LOC115148488
3 Cross references
186 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).